-
公开(公告)号:US11491223B2
公开(公告)日:2022-11-08
申请号:US16144120
申请日:2018-09-27
Applicant: AMGEN INC.
Inventor: Monica Goss , Nicole Ball
IPC: A61K38/17 , C07K14/715 , A61K39/395 , A61K47/02 , A61K47/26 , A61K9/08 , A61K47/18 , A61K9/00 , C07K19/00 , A61P19/02 , A61P17/06 , A61P29/00
Abstract: The invention relates to the formulation of pharmaceutical compositions of etanercept. The invention also relates to methods of removing buffer and of formulating pharmaceutical compositions of etanercept.
-
2.
公开(公告)号:US12214013B2
公开(公告)日:2025-02-04
申请号:US17933055
申请日:2022-09-16
Applicant: AMGEN INC.
Inventor: Monica Goss , Nicole Ball
IPC: A61P19/02 , A61K9/00 , A61K9/08 , A61K38/17 , A61K39/395 , A61K47/02 , A61K47/18 , A61K47/26 , A61K47/68 , A61P17/06 , A61P29/00 , C07K14/715 , C07K19/00
Abstract: The invention relates to the formulation of pharmaceutical compositions of etanercept. The invention also relates to methods of removing buffer and of formulating pharmaceutical compositions of etanercept.
-
公开(公告)号:US20210163531A1
公开(公告)日:2021-06-03
申请号:US17046662
申请日:2019-03-28
Applicant: AMGEN INC.
Inventor: William Callahan , Lorenzo Desantiago , Clea Talley , Yael Wexler-Cohen , Jeffrey Abel , Rahul Kaushik , Nitya Mariam Jacob , Carson Tran , Nicole Ball , Monica Goss
IPC: C07K1/36 , C07K1/34 , C07K1/18 , C07K1/16 , C07K16/28 , C07K16/30 , C07K14/535 , C07K14/505 , C07K14/71 , C07K14/715 , C07K16/40 , C07K16/32 , C07K16/22 , C07K16/18
Abstract: The invention relates to methods for preparing stable buffered and buffer-free protein compositions. The invention also relates to methods of purifying proteins from one or more impurities.
-
公开(公告)号:US20190022217A1
公开(公告)日:2019-01-24
申请号:US16144120
申请日:2018-09-27
Applicant: AMGEN INC.
Inventor: Monica Goss , Nicole Ball
Abstract: The invention relates to the formulation of pharmaceutical compositions of etanercept. The invention also relates to methods of removing buffer and of formulating pharmaceutical compositions of etanercept.
-
公开(公告)号:US20180256718A1
公开(公告)日:2018-09-13
申请号:US15958261
申请日:2018-04-20
Applicant: AMGEN INC.
Inventor: Monica Goss , Nicole Ball
CPC classification number: A61K39/39591 , A61K9/08 , A61K38/1793 , A61K47/02 , A61K47/183 , A61K47/26 , C07K14/7151 , C07K19/00 , C07K2319/30
Abstract: The invention relates to the formulation of pharmaceutical compositions of etanercept. The invention also relates to methods of removing buffer and of formulating pharmaceutical compositions of etanercept.
-
公开(公告)号:US20230080571A1
公开(公告)日:2023-03-16
申请号:US17933055
申请日:2022-09-16
Applicant: AMGEN INC.
Inventor: Monica Goss , Nicole Ball
IPC: A61K39/395 , A61K47/02 , A61K38/17 , A61K47/26 , A61K9/08 , A61K47/18 , C07K14/715 , A61K9/00
Abstract: The invention relates to the formulation of pharmaceutical compositions of etanercept. The invention also relates to methods of removing buffer and of formulating pharmaceutical compositions of etanercept.
-
公开(公告)号:US20220087901A1
公开(公告)日:2022-03-24
申请号:US17425412
申请日:2020-02-12
Applicant: AMGEN INC.
Inventor: Nicholas J. Clark , Chia-Jung Wu , Mingda Eu , Artemio A. Alanis , Jennifer Lyn Sawicky , Monica Goss , Jennifer Stevenson , Heather N. Franey , Deirdre Piedmonte , Stephen Robert Brych
Abstract: An approach for preparing a drug delivery device includes providing a prefilled delivery container and transferring a drug product contained in a drug container to the prefilled delivery container. The prefilled delivery container includes a container body containing a predetermined quantity of saline solution and a predetermined quantity of IV stabilizing solution (“IVSS”). The drug product is transferred to the prefilled delivery container via a delivery container adapter.
-
公开(公告)号:US10307483B2
公开(公告)日:2019-06-04
申请号:US15958261
申请日:2018-04-20
Applicant: AMGEN INC.
Inventor: Monica Goss , Nicole Ball
IPC: A61K38/17 , A61K39/395 , A61K47/02 , A61K47/26 , A61K9/08 , A61K47/18 , C07K14/715 , C07K19/00
Abstract: The invention relates to the formulation of pharmaceutical compositions of etanercept. The invention also relates to methods of removing buffer and of formulating pharmaceutical compositions of etanercept.
-
-
-
-
-
-
-